Injectable Drug Delivery Market to Reach $144.1 Billion by 2035

Injectable drug delivery market was valued at $67.1 billion in 2025 and is projected to reach $144.1 billion by 2035, expanding at a CAGR of 8.0% from 2026 to 2035. Market growth is supported by the increasing use of injectable medicines for chronic diseases, rising demand for self-administration, and the development of advanced drug-delivery devices for biologic therapies. According to the World Health Organization (WHO), the number of people living with diabetes worldwide increased from 200 million in 1990 to 830 million in 2022, creating substantial long-term demand for insulin and other diabetes treatments. These treatment requirements support the use of conventional syringes, prefilled syringes, pen injectors, autoinjectors, and other subcutaneous delivery technologies across healthcare facilities and homecare settings.

Browse the full report description of “Injectable Drug Delivery Market Size, Share & Trends Analysis Report, By Device Type (Conventional Syringes, Prefilled Syringes, Auto-Injectors, Pen Injectors, Wearable Injectors, Needle-Free Injectors & Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Healthcare & Others), By Application (Diabetes, Oncology, Vaccination, Cardiovascular Diseases, Autoimmune Diseases & Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/injectable-drug-delivery-market

Oncology and vaccination also contribute to the need for injectable administration technologies. The International Agency for Research on Cancer (IARC) estimated that 20 million new cancer cases and 9.7 million cancer deaths occurred globally in 2022, reinforcing the importance of reliable drug-delivery systems for cancer treatment. In immunization, WHO and UNICEF reported that approximately 115 million infants received at least one dose of a diphtheria, tetanus, and pertussis (DTP)-containing vaccine in 2024, while around 109 million completed the three-dose series. These figures demonstrate the scale of treatment and immunization activities involving injectable administration, although they do not directly measure demand for commercial drug-delivery devices. Device manufacturers are developing delivery systems to address requirements related to dose accuracy, ease of use, drug compatibility, and administration in different healthcare settings.

Diabetes Applications Drive Demand for Advanced Injectable Drug Delivery Systems

The diabetes application segment is closely linked to injectable drug delivery because insulin remains essential for people with type 1 diabetes and is required by some people with type 2 diabetes. WHO estimates that approximately 60 million people with type 2 diabetes need insulin to achieve optimal blood-glucose control, while access to treatment remains uneven. WHO's global diabetes coverage targets include ensuring that 100% of people with type 1 diabetes have access to affordable insulin and blood-glucose self-monitoring by 2030. These treatment needs support the use of conventional syringes, insulin pens, and automated subcutaneous delivery systems. Device selection depends on treatment requirements, patient preferences, clinical suitability, and access to medicines and healthcare services.

Regulatory developments are also shaping the range of technologies available for insulin administration. In January 2026, the U.S. Food and Drug Administration (FDA) determined that the MiniMed 780G Insulin Pump and associated kit were substantially equivalent to a legally marketed device through the 510(k) pathway. The system is designed to support automated insulin delivery for diabetes management. This decision reflects continued development in automated subcutaneous insulin-delivery technology, alongside conventional syringes, pen injectors, and other delivery formats. However, an insulin pump is distinct from a wearable injector in device design and delivery method, so this clearance should be interpreted as evidence of innovation in the broader diabetes drug-delivery landscape rather than as a direct indicator of wearable-injector market growth.

Recent Developments

• In March 2026, Gerresheimer introduced Gx InMonit, a reusable smart add-on for autoinjectors that guides patients through the injection process, detects injection events and potential administration failures, and automatically transfers administration data to the cloud. The solution can connect with Gx AdheraLink, an AI-driven patient-support platform that provides personalized reminders and follow-up messaging, supporting adherence to home-based injectable therapies.

• In October 2025, SCHOTT Pharma launched its 5.5 mL prefillable staked-needle glass syringe, compatible with Ypsomed’s YpsoMate 5.5 large-volume autoinjector. The launch expands large-volume injectable delivery options for biologics and supports the shift toward self-administration and home-based injectable therapies.

Market Coverage

• The market size available for 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Device Type
  • By End User
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Becton, Dickinson and Company, Gerresheimer AG, SCHOTT Pharma AG & Co. KGaA, West Pharmaceutical Services, Inc., and Ypsomed Holding AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Injectable Drug Delivery Market Report Segment

By Device Type

• Conventional Syringes
• Prefilled Syringes
• Auto-Injectors
• Pen Injectors
• Wearable Injectors
• Needle-Free Injectors
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Home Healthcare
• Others

By Application

• Diabetes
• Oncology
• Vaccination
• Cardiovascular Diseases
• Autoimmune Diseases
• Others

Injectable Drug Delivery Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/injectable-drug-delivery-market